Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

TDV · TAK-003

Vaccine (Peptide vaccine) · Immune activation · developed by TAKEDA PHARMACEUTICAL CO

Phase 3 Most advanced trial

TAK Developer

1 Registered trials

What is TDV?

TDV (TAK-003) is a vaccine studied for the prevention of dengue fever caused by dengue virus serotypes 1-4.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: TAK-003
Drug type: Vaccine (Peptide vaccine)
Mechanism: Immune activation
Therapy area: Infectious disease
Developer: TAKEDA PHARMACEUTICAL CO (TAK)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06579755	Phase 3	Dengue Fever	Active not recruiting	TAK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dengue Fever

More from TAKEDA PHARMACEUTICAL CO

Maribavir FDA approved Susoctocog Alfa FDA approved Vedolizumab FDA approved Vonicog Alfa FDA approved Elritercept Phase 3 GDX012 Phase 1/2 IGI Phase 3 Mezagitamab Phase 3 MNI-792 Phase 1 Pevonedistat Phase 2/3 Soticlestat Phase 3 TAK-186 Phase 1/2

Follow TAK, the company behind TDV

See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TAK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z